Drugmaker Valeant raises profit forecast; shares spike
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
RBC Capital Comments on Valeant (VRX) Earnings
May 9, 2017 10:29 AM EDTRBC Capital maintains Sector Perform Valeant Pharmaceuticals (NYSE: VRX).
Analyst Douglas Miehm comments to clients that his team requires more details relating to Branded Rx revenues even though most investors seem to "find comfort in the Adj. EBITDA guidance increase." He closes... More
